Skip to main content

Selected Publications


Regulatory trends of organophosphate and pyrethroid pesticides in cannabis and applications of the Comparative Toxicogenomics Database and Caenorhabditis elegans

Journal Article Toxicological Sciences · April 1, 2025 AbstractOrganophosphate and pyrethroid pesticides are common contaminants in cannabis. Due to the status of cannabis as an illicit Schedule I substance at the federal level, there are no unified national gui ... Full text Cite

Caenorhabditis elegans Neurotoxicity Testing: Novel Applications in the Adverse Outcome Pathway Framework

Journal Article Frontiers in Toxicology · March 16, 2022 Neurological hazard assessment of industrial and pesticidal chemicals demands a substantial amount of time and resources. Caenorhabditis elegans is an established model organism in developmental biology and neuroscience. ... Full text Cite

The Nesprin-1/-2 ortholog ANC-1 regulates organelle positioning in C. elegans independently from its KASH or actin-binding domains

Journal Article eLife · April 16, 2021 KASH proteins in the outer nuclear membrane comprise the cytoplasmic half of linker of nucleoskeleton and cytoskeleton (LINC) complexes that connect nuclei to the cytoskeleton. Caenorhabditis el ... Full text Cite

Xenobiotic metabolism and transport in Caenorhabditis elegans.

Journal Article Journal of toxicology and environmental health. Part B, Critical reviews · February 2021 Caenorhabditis elegans has emerged as a major model in biomedical and environmental toxicology. Numerous papers on toxicology and pharmacology in C. elegans have been published, and this species has now been adopted by investigators in academ ... Full text Cite

Regulatory Status of Pesticide Residues in Cannabis: Implications to Medical Use in Neurological Diseases.

Journal Article Current research in toxicology · January 2021 Medical cannabis represents a potential route of pesticide exposure to susceptible populations. We compared the qualifying conditions for medical use and pesticide testing requirements of cannabis in 33 states and Washington, D.C. Movement disorders were t ... Full text Cite